Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang, Xiangbin Xing, Sai‐Ching J. Yeung, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 1, pp. e003497-e003497
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Esophageal cancer in China: Practice and research in the new era
Hongcheng Zhu, Xiao Ma, Ting Ye, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 9, pp. 1741-1751
Open Access | Times Cited: 114
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer
Fan Ge, Zhenyu Huo, Xiuyu Cai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2239778-e2239778
Open Access | Times Cited: 70
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Zhichao Liu, Yaru Zhang, Ning Ma, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1852-1870.e9
Open Access | Times Cited: 51
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Xiaofeng Chen, Xiang Xu, Danping Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e005830-e005830
Open Access | Times Cited: 45
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2549-2557
Open Access | Times Cited: 38
Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
Yongkui Yu, Fanyu Meng, Xiufeng Wei, et al.
Journal of Thoracic and Cardiovascular Surgery (2024) Vol. 168, Iss. 2, pp. 417-428.e3
Closed Access | Times Cited: 17
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Zhaoqing Tang, Yan Wang, Dan Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 63
Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis
Zhaoyang Wang, Changjian Shao, Yuanyong Wang, et al.
International Journal of Surgery (2022) Vol. 104, pp. 106767-106767
Closed Access | Times Cited: 60
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Mojun Zhu, Chunhua Chen, Nathan R. Foster, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 14, pp. 3021-3031
Open Access | Times Cited: 51
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
Guoqing Zhang, Jing Yuan, Chaohu Pan, et al.
EBioMedicine (2023) Vol. 90, pp. 104515-104515
Open Access | Times Cited: 26
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
Baihua Zhang, Hongbo Zhao, Xun Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
Yong Li, Aiping Zhou, Shuoyan Liu, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
Xin Xu, Zhiyong Sun, Qiang Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008631-e008631
Open Access | Times Cited: 12
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
Ning Jiang, Jingyuan Zhang, Zhen Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008229-e008229
Open Access | Times Cited: 10
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Daniel Park, Won Jin Jeon, Chieh Yang, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 318-318
Open Access | Times Cited: 10
A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer
Minghao Li, Hongfu Sun, Wenfeng Yang, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 119, Iss. 3, pp. 896-901
Closed Access | Times Cited: 8
Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma
Gang Ji, Qi Yang, Song Wang, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 8
Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
Zhi Zhang, Jinjun Ye, Hui Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
Yujin Qiao, Cong Zhao, Xiangnan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
Shaowu Jing, Chang Zhai, Wei Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
Yunsong Liu, Yongxing Bao, Xu Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study
Hui‐min Lian, Jia-liang Wu, W.J. Liufu, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 3
Open Access | Times Cited: 7
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
Qing Li, Ting Liu, Zhenyu Ding
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
Jing Wen, Shuogui Fang, Yi Hu, et al.
EBioMedicine (2022) Vol. 86, pp. 104371-104371
Open Access | Times Cited: 23
The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
Huilai Lv, Chao‐Yuan Huang, Jiachen Li, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top